Resources Repository
-
ArticlePublication 2017Simulation of Growth Trajectories of Childhood Obesity into Adulthood
The authors developed a simulation model to estimate the risk of adult obesity at the age …
The authors developed a simulation model to estimate the risk of adult obesity at the age of 35 years for the current population of children in the United States. They used pooled height and weight data from five nationally representative longitudinal studies totaling 176,720 observations from 41,567 children and adults to simulate growth trajectories across the life course adjusted for secular trends. Using 1,000 virtual populations of 1 million children through the age of 19 years, representative of the…
Chronic Disease/Risk | Health Outcomes | Microsimulation | Child/Nutrition | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Screening for Hypertension and Counseling for Prevention
This article aimed to compare the health and economic impact of 3 services recommended by …
This article aimed to compare the health and economic impact of 3 services recommended by the US Preventive Services Task Force for the primary prevention of cardiovascular disease (CVD): (1) aspirin counseling for the primary prevention of CVD and colorectal cancer, (2) screening and treatment for lipid disorders (usually high cholesterol), and (3) screening and treatment for hypertension. A microsimulation model was used to compare lifetime outcomes from the societal perspective for a US-representative birth…
Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Policy/Regulation | Clinical Care | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this …
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this article compared the cost-effectiveness of intensive versus standard control in adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control. A microsimulation model was used to project lifetime costs of treatment and monitoring, cardiovascular disease events and subsequent treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for the two strategies.…
Chronic Disease/Risk | Health Outcomes | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | North America -
ArticlePublication 2017Benefit and Harm of Intensive Blood Pressure Treatment: Derivation and Validation of Risk Models Using Data from the Sprint and Accord Trials
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some …
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. The authors sought to create risk calculators to estimate individual patients’ chances of benefit and harm from intensive treatment. They developed statistical models of cardiovascular events and serious adverse events from individual participant data from the Systolic Blood Pressure Intervention Trial (SPRINT) of intensive blood pressure treatment (N = 9,069 with complete covariate data) and validated them…
Chronic Disease/Risk | Probability/Bayes | Health Outcomes | Evidence Synthesis -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Chronic Disease/Risk | Test Performance | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Chronic Disease/Risk | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Chronic Disease/Risk | Preferences/Values | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | North America | Europe -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Chronic Disease/Risk | Costing Methods | Benefit-Cost Analysis | Policy/Regulation | Government/Law | Health/Medicine | North America -
ArticlePublication 2017OOP Expenditures for Cardiovascular Disease
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of …
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of catastrophic health expenditure (CHE) and factors associated with CHE for the prevention and treatment of cardiovascular disease in hospitals in Addis Ababa. Seeking prevention and treatment services for cardiovascular disease in Addis Ababa was found to pose substantial financial burden on households, affecting the poorest and those who reside outside Addis Ababa more. Economic and geographic inequalities should therefore be…
Chronic Disease/Risk | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Sub-Saharan Africa